BSD Medical Reports on Continued Sales Momentum by Terumo for the MicroThermX® Microwave System

  BSD Medical Reports on Continued Sales Momentum by Terumo for the
  MicroThermX® Microwave System

Terumo to Focus on MicroThermX Introduction in Eastern European and Middle
Eastern Markets Following Early Success in Western Europe

Business Wire

SALT LAKE CITY -- March 3, 2014

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (, a
leading provider of medical systems that treat cancer and benign diseases
using heat therapy, today reported continued sales momentum by Terumo on the
distribution of the MicroThermX^® Microwave Ablation System (MicroThermX).
BSD’s exclusive, multimillion dollar agreement with Terumo Europe NV (Terumo)
covers distribution of the MicroThermX in more than 100 countries, including
Europe, Western Asia and Africa, with a market potential that exceeds $1

“Terumo has been an exceptional partner for BSD, making substantial
investments in sales and marketing of the MicroThermX,” said Sam Maravich,
Vice President of Sales and Marketing of BSD Medical. “We are gaining sales
traction in the Western European countries. The next phases of Terumo’s plan
are focused on expanding into Eastern European markets, with the Middle East
to follow. Since the beginning of BSD's 2014 fiscal year, Terumo has initiated
marketing efforts in countries with the highest revenue potential. Terumo
continues to execute on plan and we view this partnership as a model for
future distribution collaborations with the MicroThermX system.”

Terumo is implementing a well-planned, comprehensive marketing strategy for
the MicroThermX that is aimed at geographic expansion and building credibility
within the clinical community. Among key aspects of the marketing strategy,
Terumo is using its significant relationships within the clinical community to
establish MicroThermX teaching centers of excellence with key opinion leaders.
Terumo is also sponsoring several studies with the MicroThermX.

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional
oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of
nearly $5 billion and has a market cap in excess of $8 billion. Through the
sale and promotion of a high-quality line of devices used for tumor
embolization, the closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional oncology.

About the MicroThermX Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX is the first of its kind that allows delivery of higher power
levels using a single generator.

The MicroThermX utilizes innovative synchronous phased array technology that
was developed and patented by MicroThermX BSD to provide a wide range of
uniform zones of ablation. The MicroThermX includes innovative, high-end
disposables (SynchroWave antennas) that are used in each ablation treatment
and will provide a significant ongoing revenue stream.

The soft tissue (tumor) ablation world market potential is estimated to exceed
$2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX ^ for ablation of soft
tissue. BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX in Europe. CE Marking is also recognized
in many countries outside of the EU, providing BSD the ability to market the
MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
microwave energy and radiofrequency (RF). BSD’s product lines include ablation
and hyperthermia treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market, and well established distribution in the United States, Europe and
Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat certain
tumors with heat (hyperthermia), while increasing the effectiveness of other
therapies such as radiation therapy. Certain of the Company’s products have
received regulatory approvals in the United States, Europe and China. For
further information visit BSD Medical's website at

Forward-Looking Statements

Statements contained in this press release that are not historical facts,
including statements relating to our 2014 plans, are forward-looking
statements, as defined in the Private Securities Litigation Reform Act of
1995. All forward-looking statements are subject to risks and uncertainties
detailed in the Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the regulatory
requirements we face. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date, except as required by law.


BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
Press spacebar to pause and continue. Press esc to stop.